Vertex Pharmaceuticals | VRTX

Stock Price
478.64
Daily Change
4.37 0.92%
Monthly
4.32%
Yearly
-2.64%
Q1 Forecast
481.63



Peers Price Chg Day Year Date
AbbVie 235.51 1.65 0.71% 11.33% Mar/04
Acadia Pharmaceuticals 23.24 0.74 3.27% 28.51% Mar/04
Agios Pharmaceuticals 28.95 0.47 1.65% -14.73% Mar/04
Alnylam Pharmaceuticals 327.33 8.68 2.72% 31.34% Mar/04
Amgen 379.07 2.07 0.55% 19.74% Mar/04
Arrowhead Research 64.47 0.37 0.58% 271.59% Mar/04
Biogen 188.62 4.60 2.50% 31.20% Mar/04
BioMarin Pharmaceutical 60.90 2.37 4.05% -14.45% Mar/04
Bristol-Myers Squibb 62.27 1.05 1.72% 4.10% Mar/04
Gilead Sciences 148.44 0.61 0.41% 28.59% Mar/04

Indexes Price Day Year Date
US500 6889 72.58 1.06% 17.91% Mar/04
USND 22883 365.83 1.62% 23.34% Mar/04
US400 3542 1.13 0.03% 17.53% Mar/04
US100 25187 466.71 1.89% 22.10% Mar/04

Vertex Pharmaceuticals traded at $477.24 this Wednesday March 4th, increasing $2.97 or 0.63 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 4.02 percent. Over the last 12 months, its price fell by 2.93 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 481.63 by the end of this quarter and at 438.75 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.



News Stream
Vertex Pharmaceuticals Stock Price Hits 5-week High
Vertex Pharmaceuticals shares increased to 486.00 USD, the highest since January 2026. Over the past 4 weeks, Vertex Pharmaceuticals gained 4.15%, and in the last 12 months, it increased 2.37%.
2026-02-13
Vertex Pharmaceuticals Stock Price Hits 5-week Low
Vertex Pharmaceuticals shares decreased to 443.02 USD, the lowest since December 2025. Over the past 4 weeks, Vertex Pharmaceuticals lost 2.65%, and in the last 12 months, it increased 4.57%.
2026-01-15
Vertex Pharmaceuticals Stock Price Hits 25-week High
Vertex Pharmaceuticals shares increased to 480.80 USD, the highest since July 2025. Over the past 4 weeks, Vertex Pharmaceuticals gained 8.76%, and in the last 12 months, it increased 16.66%.
2026-01-07